Recombinant Viral CMV UL146/ vCXC1 (Catalog # 620-CM) chemoattracts the BaF3 mouse pro-B cell line transfected with human CXCR2 in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin (Catalog # AR002). Chemotaxis elicited by Recombinant Viral CMV UL146/vCXC1 (0.3 µg/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Viral CMV UL146/ vCXC1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF620). The ND₅₀ is typically 10-30 µg/mL.

Applications for Viral CMV UL146/vCXC1 Antibody

Application

Recommended Usage

Western Blot

0.1 µg/mL
Sample: Recombinant Viral CMV UL146/vCXC1 (Catalog # 620-CM)

Neutralization

Measured by its ability to neutralize CMV UL146/vCXC1-induced chemotaxis in the BaF3 mouse pro-B cell line transfected with human CXCR2. The Neutralization Dose (ND₅₀) is typically 10-30 µg/mL in the presence of 0.3 µg/mL Recombinant Viral CMV UL146/vCXC1.

Formulation, Preparation, and Storage

Purification

Antigen Affinity-purified

Reconstitution

Reconstitute at 0.2 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: UL146/vCXC1

Cytomegalovirus (CMV), a member of the beta herpesvirus subfamily, typically causes subclinical or latent infections in the normal adult population. However, CMV can cause congenital disease during pregnancy and is a human opportunistic pathogen that affects immunocompromised individuals. The CMV genome has been shown to contain homologs of cellular immunomodulatory proteins, including US28 (a CC chemokine receptor) and a MHC class I homolog. Virulent CMV clinical isolates have also been shown to carry at least 19 genes, designated UL133-UL151, that are not found in laboratory strains that have lost virulence characteristics. Two of these genes, UL146 and UL147, exhibit sequence similarity to CXC chemokines.

The CMV UL146 open-reading frame encodes a 117 amino acid residue precursor protein with a predicted 22 residues signal peptide that is cleaved to generate the mature protein. Recombinant UL146 has been shown to induce calcium mobilization, chemotaxis and degranulation of neutrophils.

References

Dairaghi, D. et al. (1998) Sem. Virol. 8:377.
Cha, T.A. et al. (1996) J. Virol.70:78.

Long Name

Cytomegalovirus UL146

Alternate Names

HHV5wtgp117, vCXC1, vCXCL1, Y18

Additional UL146/vCXC1 Products

Product Documents for Viral CMV UL146/vCXC1 Antibody

Product Datasheets

Download Product Datasheets

COA

SDS

Download SDS

Product Specific Notices for Viral CMV UL146/vCXC1 Antibody

For research use only

Citations
Reviews

Viral CMV UL146/vCXC1 Antibody

R&D Systems, part of Bio-Techne | Catalog # AF620

Key Product Details

Species Reactivity

Validated:

Cited:

Applications

Validated:

Cited:

Label

Antibody Source

View all UL146/vCXC1 Antibodies »

Product Specifications

Immunogen

Specificity

Clonality

Host

Isotype

Endotoxin Level

Scientific Data Images for Viral CMV UL146/vCXC1 Antibody

Chemotaxis Induced by CMV UL146/vCXC1 and Neutralization by CMV UL146/vCXC1 Antibody.